New drug combo shows promise in early cancer trial

NCT ID NCT02495896

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug called sEphB4-HSA combined with standard chemotherapy in people with advanced or metastatic solid tumors, including head and neck, pancreatic, lung, and gallbladder cancers. The goal is to find the best dose and see if the combination is safe and works better than chemo alone. About 61 participants are enrolled, and the study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
recombinant EphB4-HSA fusion protein (sEphB4-HSA) combined with standard chemotherapy drugs (cisplatin, gemcitabine, docetaxel, paclitaxel)
What this could lead to
If this works, it could point toward a more effective treatment for several advanced cancers that are hard to treat, like pancreatic and lung cancer.
What could go wrong
This is a very early (Phase 1) pilot study with only 61 people, so it's mainly checking safety and dosing. The combination may not work better than chemo alone, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California, 92663, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.